DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Tandem Auto-Allo Transplant for Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Low-Grade
T-Cell Lymphoma
Diffuse, Large B-Cell, Lymphoma
Mantle-Cell Lymphoma
Chronic Lymphocytic Leukemia
Lymphoma, Small Lymphocytic
Hodgkin's Lymphoma

Interventions: Drug: Busulfan (conditioning for AUTO transplant)
Drug: Etoposide (conditioning for AUTO transplant)
Drug: Cyclophosphamide (conditioning for AUTO transplant)
Drug: Mesna (prior to AUTO transplant)
Other: autologous (auto) peripheral blood stem cell transplantation
Drug: Neupogen
Drug: Fludarabine (conditioning for ALLO Transplant)
Drug: Busulfan (conditioning for ALLO Transplant)
Other: non-myeloablative allogeneic (allo) transplant
Drug: Tacrolimus
Drug: Sirolimus
Drug: Methotrexate

First Posted Date: 2010-08-13

Last Posted Date: 2017-03-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 42

Registration Number: NCT01181271

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Vitamin D Deficiency in Adolescent Girls

Not Applicable

Completed

Conditions: Vitamin D Deficiency
Healthy

Interventions: Dietary Supplement: ergocalciferol
Other: placebo pill

First Posted Date: 2010-08-12

Last Posted Date: 2013-11-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 90

Registration Number: NCT01180946

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment

Active, not recruiting

Conditions: Brain Tumor
Central Nervous System Neoplasms

First Posted Date: 2010-08-12

Last Posted Date: 2025-02-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 155

Registration Number: NCT01180881

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Pathogenesis of Chronic Sinusitis in Relationship to Tobacco Smoke Exposure

Not Applicable

Completed

Conditions: Chronic Rhinosinusitis

Interventions: Other: Biopsy

First Posted Date: 2010-08-11

Last Posted Date: 2018-05-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 97

Registration Number: NCT01179139

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Smoking Interventions for Hospital Patients

Not Applicable

Completed

Conditions: Cigarette Smoking

Interventions: Other: Standard Care
Other: Extended Care Management

First Posted Date: 2010-08-06

Last Posted Date: 2014-09-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 397

Registration Number: NCT01177176

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Cognitive-Behavior Therapy for Young Adults With Bipolar Disorder

Phase 1

Completed

Conditions: Bipolar Disorder

Interventions: Behavioral: cognitive-behavior therapy (CBT)

First Posted Date: 2010-08-06

Last Posted Date: 2012-04-26

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 55

Registration Number: NCT01176825

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: dasatinib
Drug: Rituximab
Drug: fludarabine

First Posted Date: 2010-08-02

Last Posted Date: 2017-04-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT01173679

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: recombinant human growth hormone (rhGH)

First Posted Date: 2010-07-23

Last Posted Date: 2021-11-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 22

Registration Number: NCT01169103

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophagogastric Cancer

Interventions: Drug: STA-9090

First Posted Date: 2010-07-22

Last Posted Date: 2023-11-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT01167114

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders

Terminated

Conditions: Idiopathic Hypogonadotropic Hypogonadism
Hypothalamic Amenorrhea

First Posted Date: 2010-07-20

Last Posted Date: 2011-05-24

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT01165619

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy